Showing results for "s gail eckhardt"
Showing 1 - 1 of 1 Results
Adult content is visible.
2010
EN
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
People who read this also enjoyed
2016
EN
This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike.The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the cent...
Hodgkin's Lymphoma, An Issue of Hematology/Oncology
Hodgkin's Lymphoma, An Issue of Hematology/Oncology
- Book Volume 28-1 -
- The Clinics: Internal Medicine
2014
EN
This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , “Normal“ CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.
Childhood Leukemia
A Practical Handbook
- Series -
- Medicine (R0)
2011
EN
This book is a comprehensive and up-to-date compendium on all aspects of childhood leukemia. After introductory chapters on the epidemiology and biology of pediatric leukemia, treatment considerations are extensively reviewed, with emphasis on the use of risk-adjusted treatment approaches. Promising targeted agents are discussed, and strategies for the development of new agents are appraised. The late effects of leukemia and its therapy are then considered in depth, with due attention to m...
- Book Volume 27-2 -
- The Clinics: Internal Medicine
2013
EN
This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments,What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 ...
Glioblastoma:
Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies
- Series -
- Biomedical and Life Sciences (R0)
2009
EN
Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating...
Cancer Immunotherapy
Paradigms, Practice and Promise
- Series -
- Biomedical and Life Sciences (R0)
2012
EN
This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.
- Series -
- Medicine (R0)
2013
EN
The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequency over the past decade owing to increased recognition, improved understanding, and an aging population. This book, completely updated since the first edition, summarizes in a concise and focused way the current knowledge of all aspects of MDS. Clinical presentation, etiology, epidemiology, molecular biology, classification, and staging are...
Combining Targeted Biological Agents with Radiotherapy
Current Status and Future Directions
2008
EN
Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer patients will receive radiotherapy at some point in their treatment. A major improvement in patient outcomes occurs with the use of combined chemotherapy and radiotherapy. The combination of targeted biological agents with radiotherapy is the latest cutting-edge extension in cancer therapy for radiation oncologists.Combining Targeted Biological Agents with Radiotherapy: Current Status and Futur...
Clinical Trials
Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
2011
EN
Accessible
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. Thi...
2010
EN
Breast Cancer:Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer.Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments...
- Book Volume 22-4 -
- The Clinics: Surgery
2013
EN
This issue of the Surgical Oncology Clinics of North America, Guest Edited by Dr. William G. Cance, is devoted to Translational Cancer Research for Surgeons. Translational Cancer research aims to move bench research to the bedside by applying basic science toward potential therapies. This issue will present the concepts of translational research and development of targeted therapeutics, and its implications for surgeons. It will show clinical applications for surgeons regarding sarcoma/GIS...











